Clinical trial · Interventional
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia
"Phase II Multicenter Study Evaluating the Efficacy and the Safety of a Combination of Nilotinib Plus Pegylated Interferon Alpha 2a for de Novo Chronic Phase Chronic Myelogenous Leukemia Patients"
NCT01294618CI-TRIAL-00038814NILOPEGcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to demonstrate the safety and the efficacy of a combination of 2 treatments shown to have some efficacy in Chronic Phase Chronic Myelogenous Leukemia (CP CML) separately, but that have never been combined to date, and this combination is expected to substantially increase the molecular response rates.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myelogenous Leukemia | Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- nilotinib + pegylated interferon alpha 2a (PEG-IFN).
- interventionNames
- Drug: Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.
Primary outcomes (1)
- measure
- Cumulative incidence of complete molecular remissions after 12 months of treatment with nilotinib + Pegylated Interferon (PEG-IFN)
- timeFrame
- 24 months
- description
- The trial opens for enrolment in 2011 March 7th for 18 months. Each patient will be followed for 24 months after entry.
Secondary outcomes (11)
- measure
- Kinetics of Complete Molecular Response (CMR) at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months.
- timeFrame
- Patients will be enrolled for 18 months and will be followed for 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Performans status 0-2 * CP CML diagnosed since less than 3 months without previous Tyrosine Kinase Inhibitor (TKI) or interferon treatment * Adequate organic functions: * Total Bilirubin \< 1.5xUpper Normal Range (UNR). * Aspartate Amino Transferase (ASAT) and Alanine Amino Transferase (ALAT) \< 2.5xUNR. * Alkaline phosphatase ≤ 2.5xUNR * Amylase and lipase ≤ 1.5xUNR. * Creatininemia \< 1.5xUNR. * Biological blood standards : * Potassium ≥ Lower Normal Range (LNR) * Magnesium ≥ LNR. * Phosphorus ≥ LNR * Calcium ≥ LNR. * Negative pregnancy test within the last 7 days for women with childbearing potential. * Informed consent signed up * Compliance to tretament ensured, * Valid social insurance Exclusion Criteria: Prior TKI or interferon treatment for the CML * Contra-indication to IFN * Pregnancy, breast feeding * Human Immunodeficiency Virus positive, chronic hepatitis B or C. * Other BCR-ABL transcript than M-bcr * Cardiopathy defined as: * Left Ventricular Ejection Fraction (LVEF) \< 45%. * Left bundle branch block * Ventricular pacemaker. * Congenital prolonged QT * Past ventricular or significant auricular tachyarrythmia * Clinically significant bradycardia (\<50 per minute). * QTc (Fredericia) \> 450 ms (average on 3 Elektrokardiogramm (EKG)). * Myocardial infarction in the last 12 months. * Unstable angina within the last 12 months. * Other significant cardiac diseases. * Other uncontrolled severe disease (such as diabetes melittus etc…) * Other ongoing malignant disease. * Past history of congenital or acquired clinically significant bleeding disorder. * Previous radiotherapy ≥25% of bone marrow. * Serious surgery within the past 4 weeks * Investigational treatment within the last 30 days prior to day 1. * History of non compliance. * Cytochrome P450 3A4 (CYP3A4) inhibitors that could not be withdrawn or modified (such as erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil). * Severe gastro-intestinal disorders (such as gastric ulcer, uncontrolled nausea, malabsorption syndrome, small intestine resection, gastric shunt). * Hepatic, renal or pancreatic chronic disorder unrelated to CML * Recent history of acute pancreatitis within a year or history of chronic pancreatic disease . * Any concommittant treatment inducing QT prolongation.
References
Publications (1)
- RESULTNicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Ame S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7. PMID 26687426